Physician profile
Pradeep Kumar
NPI 1093790537
$131,362.54
in general payments reported to CMS, 2019-2025
41 companies · $39K in 2025
The $39K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,429 · 2020: $14K · 2021: $19K · 2022: $13K · 2023: $22K · 2024: $17K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Travel and Lodging: $9,777 · Food and Beverage: $7,740 · Education: $17.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,000.00 |
| Travel and Lodging | $9,777.21 |
| Food and Beverage | $7,739.53 |
| Education | $17.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $124,282.54 | 2019-2025 | |
| Pfizer INC. | $1,069.23 | 2019-2025 | |
| Celgene Corporation | $807.52 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $766.06 | 2019-2024 | Xifaxan |
| Janssen Scientific Affairs, LLC | $583.61 | 2019-2024 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $341.49 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $312.33 | 2021-2023 | |
| Janssen Biotech, INC. | $274.30 | 2019-2024 | Stelara, Tremfya |
| Aimmune Therapeutics, INC. | $264.80 | 2024-2025 | Zenpep, Vowst |
| Redhill Biopharma INC. | $212.59 | 2020-2023 | |
| Genzyme Corporation | $209.57 | 2023-2025 | |
| Boston Scientific Corporation | $192.91 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $167.50 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $163.95 | 2019-2025 | Eohilia, Gattex, Entyvio |
| Daiichi Sankyo INC. | $153.54 | 2019-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $150.70 | 2020-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $146.69 | 2024-2025 | Resmetirom, Rezdiffra |
| Ironwood Pharmaceuticals, INC | $132.20 | 2019-2024 | |
| Exact Sciences Corporation | $130.00 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $111.57 | 2023-2024 | Dificid |
| Ardelyx, INC. | $101.06 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $94.26 | 2024-2025 | Sucraid, Sucraid |
| Amarin Pharma, INC. | $85.94 | 2019 | |
| Phathom Pharmaceuticals, INC. | $84.28 | 2024-2025 | Voquezna |
| Medtronic, INC. | $75.46 | 2023 | Gi Genius |
| Braintree Laboratories, INC. | $73.38 | 2020-2025 | Suflave, Sutab |
| Lilly USA, LLC | $68.45 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $58.24 | 2024-2025 | Vegzelma, Zymfentra |
| Vivus LLC | $39.11 | 2024 | Qsymia |
| Supernus Pharmaceuticals, INC. | $31.40 | 2021 | |
| Albireo Pharma, INC. | $23.90 | 2024 | Iqirvo |
| Shire North American Group INC | $21.87 | 2019 | |
| Ethicon US, LLC | $19.85 | 2019 | |
| Abbott Laboratories | $19.84 | 2023 | Assurity |
| Janssen Pharmaceuticals, INC | $17.93 | 2021 | |
| Organon LLC | $16.86 | 2024 | |
| Romark Laboratories, Lc | $15.90 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.97 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $14.12 | 2021 | |
| Endo Pharmaceuticals INC. | $12.62 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradeep Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.